Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EPI 001

Known as: EPI-001, EPI001 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Multiple androgen receptor (AR)‐dependent and ‐independent resistance mechanisms limit the efficacy of current castration… Expand
2017
2017
Prostate cancer (PCa) is the 2nd leading cause of cancer-related death among men in the United States and its progression is… Expand
2016
2016
Castration-resistant prostate cancer is the lethal condition suffered by prostate cancer patients that become refractory to… Expand
Highly Cited
2015
Highly Cited
2015
The androgen receptor (AR) is a driver of prostate cancer (PCa) cell growth and disease progression. Therapies for advanced PCa… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2015
Review
2015
Reactivated androgen receptor (AR) signaling drives castration‐resistant prostate cancer (CRPC). The novel AR targeting drugs… Expand
Highly Cited
2013
Highly Cited
2013
Hormone therapies for advanced prostate cancer target the androgen receptor (AR) ligand-binding domain (LBD), but these… Expand
  • figure 1
  • figure 4
  • figure 5
  • figure 6
  • figure 7
Highly Cited
2013
Highly Cited
2013
Androgen receptor signaling is critical in the development and progression of prostate cancer, leading to intensive efforts to… Expand
  • table 1
Review
2011
Review
2011
  • M. Sadar
  • Cancer research
  • 2011
  • Corpus ID: 935672
Androgen ablation therapy remains the gold standard for the treatment of advanced prostate cancer, but unfortunately, it is not… Expand
  • figure 1
Highly Cited
2010
Highly Cited
2010
Castration-recurrent prostate cancer (CRPC) is suspected to depend on androgen receptor (AR). The AF-1 region in the amino… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2010
2010
recurrent prostate cancer (CRPC) is generally believed to involve the androgen receptor (AR) in most patients. Current treatments… Expand